Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma

Table 1 Clinicopathologic characteristics of esophageal squamous cell carcinoma patients n (%)

Characteristics	Total(n = 200)	PD-L1 status		P value
		Negative(n = 133)	Positive(n = 67)
Age, median years (range)	65 (41-83)	65 (50-83)	64 (41-82)	0.5191
Sex
Male	188 (94.0)	125 (94.0)	63 (94.0)
Female	12 (6.0)	8 (6.0)	4 (6.0)	1.000
Smoking history	168 (84.9)	110 (84.0)	58 (86.6)	0.630
Alcoholic intake	166 (84.3)	110 (84.0)	56 (84.9)	0.873
Stage
I	66 (33.0)	47 (35.3)	19 (28.4)
II	59 (29.5)	41 (30.8)	18 (26.9)
III	71 (35.5)	44 (33.1)	27 (40.3)
IV	4 (2.0)	1 (0.8)	3 (4.5)	0.200
Differentiation
W/D	41 (23.0)	36 (27.1)	10 (14.9)
M/D	131 (65.5)	83 (62.4)	48 (71.6)
P/D	23 (11.5)	14 (10.5)	9 (13.4)	0.152
Treatment
Surgery alone	122 (61.0)	83 (62.5)	39 (58.2)
Surgery → Adj.	58 (29.0)	38 (28.6)	20 (29.9)
Neoadj. → Surgery	14 (7.0)	9 (6.8)	5 (7.5)
Neoadj. → Surgery → Adj.	6 (3.0)	3 (2.3)	3 (4.5)	0.927
Surgery results
R0 resection	176 (88.0)	121 (91.0)	55 (82.1)
R1, R2 resection	24 (12.0)	12 (9.0)	12 (17.9)	0.068
p16
Negative	179 (89.5)	121 (91.0)	58 (86.6)
Positive	21 (10.5)	12 (9.0)	9 (13.4)	0.616
H-score
< 50	158 (79.0)	112 (84.2)	46 (68.7)
≥ 50, < 100	31 (15.5)	16 (12.0)	15 (22.4)
≥ 100, < 200	11 (5.5)	5 (3.8)	6 (9.0)	0.036
Follow-up duration, median months (range)	33.2 (0.6-178.7)	33.9 (0.6-176.7)	31.7 (2.3-178.7)	0.7901

¹Estimated by Mann-Whitney test. N: Number; W/D: Well differentiated; M/D: Moderately differentiated; P/D: Poorly differentiated; Adj.: Adjuvant chemotherapy; Neoadj.: Neoadjuvant chemotherapy.